Pharmaceutical Compounding
Stability Studies of Extemporaneously Prepared Oral Formulations
Click on product name for a synopsis of drug study
Acetazolamide: Allen LV Jr., Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(16):1944-1949.
Adderall®: Justice J, Kupiec TC, Matthews P, Cardona P. Stability of Adderall in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 2001;58(15):1418-1421.
Allopurinol: Allen LV Jr., Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(16):1944-1949.
Alprazolam: Allen LV Jr., Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(18):1915-1920.
Aminophylline: Chong E, Dumont RJ, Hamilton DP, Koke PM, Ensom MHH. Stability of aminophylline in extemporaneously-prepared oral suspensions. J Inform Pharmacother. 2000;2:100-106.
Amiodarone HCl: Nahata MC, Morosco RS, Hipple TF. Stability of amiodarone in extemporaneous oral suspensions prepared from commercially available vehicles. J of Ped Pharm Prac. 1999;4(4):186-189.
Amlodipine Besylate: Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J American Pharm Assoc. 1999;39(3):375-377.
Aprepitant: Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of extemporaneous oral liquid aprepitant formulation. Support Care Cancer. 2009;17(6):701-706.
Atenolol: Patel D, Doshi DH, Desai A. Short-term stability of atenolol in oral liquid formulations. IJPC. 1997;1(6):437-439.
Azathioprine: Allen LV Jr., Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(16):1944-1949.
Baclofen: Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184.
Benazepril HCl: Physician’s Desk Reference 60th Edition, 2006, p.2234. Lotensin® product information.
Bethanechol Chloride: Allen LV Jr., Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(17):1804-1809.
Captopril: Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184.
Carbamazepine: Jover BA, Marquez PJF, Gonzalez L, Pitaluga PL, Selva OJ. Analysing the stability of two oral carbamazepine suspensions. Farm Hosp. 2010.
Celecoxib: Donnelly RF, Pascuet E, Ma C,Vaillancourt R. Stability of celecoxib oral suspension. Can J Hosp Pharm. 2009;62(6):465-468.
Chloroquine Phosphate: Allen LV Jr., Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(18):1915-1920.
Ciprofloxacin HCI: Nahata MC, Morosco RS, Hipple TF. Development of stable oral suspensions of ciprofloxacin. J of Appl Ther Res. 2000;3:61-65. Johnson CE, Wong DV, Hoppe HL, Bhatt-Mehta V. Stability of ciprofloxacin extemporaneous oral liquid dosage form. IJPC. 1998;2(4):314-317.
Cisapride: Allen LV Jr., Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(18):1915-1920.
Clonazepam: Allen LV Jr., Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(16):1944-1949.
Clonidine HCl: Levinson ML and Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. Am J Hosp Pharm. 1992;49:122-5.
Clopidogrel Bisulfate: Skillman KL, Caruthers RL, Johnson CE. Stability of an extemporaneously prepared clopidogrel oral suspension. Am J Health-Syst Pharm. 2010;67(7):559-561.
Clozapine: Walker SE, Baker D, Law S. Stability of clozapine stored in oral suspension vehicles at room temperature. Can J Hosp Pharm. 2005;58(5):279-284.
Codeine Phosphate: Dentinger PJ, Swenson CF. Stability of codeine phosphate in an extemporaneously compounded syrup. Am J Health-Syst Pharm. 2007;64(24):2569-2573.
Cyclophosphamide: Kennedy R, Groepper D, Tagen M, et al. Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother. 2010;44(2):295-301.
Dapsone: Nahata MC, Morosco RS, Trowbridge JM. Stability of dapsone in two oral liquid dosage forms. Ann Pharmacother. 2000;34(7/8):848-850.
Dexamethasone Sodium Phosphate: Wen-Lin Chou J, Decarie D, Dumont RJ, Ensom MHH. Stability of dexamethasone in extemporaneous prepared oral solutions. Can J Hosp Pharm. 2001;54(2):96-101.
Diclofenac Sodium: Donnelly RF, Pascuet E, Ma C, Vaillancourt R. Stability of diclofenac sodium oral suspensions packaged in amber polyvinyl chloride bottles. Can J Hosp Pharm. 2010;63(1):2179-2184.
Diltiazem HCl: Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184.
Dipyridamole: Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184.
Dolasetron Mesylate: Johnson CE, Wagner DS, Bussard, WE. Stability of dolasetron in two oral liquid vehicles. Am J Health-Syst Pharm. 2003;60(21):2242-2244.
Domperidone: Ensom MHH, Decarie D, Hamilton DP. Stability of domperidone in extemporaneously compounded suspensions. J Inform Pharmacother. 2002;8:100-104.
Enalapril Maleate: Allen LV Jr., Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(18):1915-1920.
Famotidine: Dentinger PJ, Swenson CF, Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 2000;57(14):1340-1342.
Flecainide Acetate: Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184.
Flucytosine: Allen LV Jr., Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(16):1944-1949. VandenBussche HL, Johnson CE, Yun J, Patel SA. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations. Am J Health-Syst Pharm. 2002;59(19):1853-1855.
Gabapentin: Nahata MC. Development of two stable oral suspensions for gabapentin. Pediatr Neurol. 1999;20(3):195-197.
Ganciclovir: Anaizi NH, Swenson CF, Dentinger PJ. Stability of ganciclovir in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1999;56(17):1738-1741.
Glycopyrrolate: Cober MP, Johnson CE, Studekum D, Penprase K. Stability of extemporaneously prepared glycopyrrolate oral suspensions. Am J Health-Syst Pharm. 2011(68):843-845.
Granisetron HCl: Nahata MC, Morosco RS, Hipple TF. Stability of granisetron hydrochloride in two oral suspensions. Am J Health-Syst Pharm. 1998;55(23):2511-2513.
Hydralazine HCl: Allen LV Jr., Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(18):1915-1920.
Hydrocortisone: Chong G, Decarie D, Ensom MHH. Stability of hydrocortisone in extemporaneously compounded suspensions. J Inform. Pharmacother. 2003;(13):100-110.
Itraconazole: Abdel-Rahman S, Nahata MC. Stability of itraconazole in an extemporaneous suspension. J Ped Pharm Prac. 1998;3(2):115-118.
Ketoconazole: Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078.
Labetolol HCl: Allen LV Jr, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(19):2304-2309.
Lamotrigine: Nahata MC, Morosco RS, and Hipple TF. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C. Am J Health-Syst Pharm. 1999;56(3):240-242.
Lansoprazole: Ensom MHH, Decarie D, Sheppard I. Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration. Can J Hosp Pharm. 2007;60(3):184-191.
Levetiracetam: Ensom MHH, Decarie D, Rudolph S. Stability of levetiracetam in extemporaneously compounded suspensions. Can J Hosp Pharm. 2011;64(3):207-211.
Levodopa/Carbidopa: Nahata MC, Morosco RS, Leguire LE. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus. 2000;37(6);333-337.
Levofloxacin: VandenBussche HL, Johnson CE, Fontana EM, Meram JM. Stability of levofloxacin in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1999;56(22):2316-2318.
Levothyroxine sodium: Boulton DW, Fawcett JP, Woods DJ. Stability of an extemporaneously compounded levothyroxine sodium oral liquid. Am J Health-Syst Pharm. 1996;53:1157-61.
Lisinopril: Thompson KC, Zhao Z, Mazakas JM, Beasley CA, Reed RA, Moser CL. Characterization of an extemporaneous liquid formulation of lisinopril. Am J Health-Syst Pharm. 2003;60(1):69-74.
Losartan Potassium: Physicians’ Desk Reference 60th ed., 2006, p.1917. Cozaar® product information.
Melatonin: Johnson CE, Cober MP, Thome T, Rouse E. Stability of an extemporaneous alcohol-free melatonin suspension. Am J Health-Syst Pharm. 2011:68(5):420-423.
Metolazone: Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078.
Metoprolol Tartrate: Allen LV Jr, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(19):2304-2309.
Metronidazole: Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078.
Moxifloxacin: Hutchinson DJ, Johnson CE, Klein KC. Stability of extemporaneously prepared moxifloxacin oral suspensions. Am J Health-Syst Pharm. 2009;66(7):665-667.
Mycophenolate Mofetil: Swenson CF, Dentinger PJ, Anaizi NH. Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid. Am J Health-Syst Pharm. 1999;56(21):2224-2226.
Naratriptan HCl: Zhang YP, Trissel LA, Fox JL. Naratriptan hcl in extemporaneously compounded oral suspensions. IJPC. 2000;4(1):69-71.
Nifedipine: Nahata MC, Morosco R, Willhite EA. Stability of nifedipine in two oral suspensions stored at two temperatures. J Am Pharm Assoc. 2002;42(6):865-867.
Nitrofurantoin: Ensom MHH, Decarie D. Stability of nitrofurantoin in extemporaneously compounded suspensions. Can J Hosp Pharm. 2006;59(1):29-33.
Norfloxacin: Johnson CE, Price J, Hession JM. Stability of norfloxacin in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 2001;58(7):577-579.
Ondansetron HCl: Williams CL, Sanders PL, Laizure SC, Stevens RC, Fox JL, Hak LJ. Stability of ondansetron hydrochloride in syrups compounded from tablets. Am J Health-Syst Pharm. 1994;51(6):806-809.
Oseltamivir Phosphate: Winiarski AP, Infeld MH, Tscherne R, et al. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm. 2007;47(6):747-755.
Oseltamivir Phosphate: Package Insert. Tamiflu. Genentech USA, Inc. 2011.
Oxandrolone: Johnson CE, Cober MP, Hawkins KA, Julian JD. Stability of extemporaneously prepared oxandrolone oral suspensions. Am J Health-Syst Pharm. 2011;68(6):519-521
Phenobarbital (alcohol-free): Cober MP, Johnson CE. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension. Am J Health-Syst Pharm. 2007;64(6):644-646.
Procainamide HCl: Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078.
Propranolol HCl: Ensom MHH, Kendrick J, Rudolph S, Decarie D. Stability of Propranolol in Extemporaneously Compounded Suspension. CJHP. 2013;66(2):118-24.
Propylthiouracil: Nahata MC, Morosco RS, Trowbridge JM. Stability of propylthiouracil in extemporaneously prepared oral suspensions at 4 and 25 degrees C. Am J Health-Syst Pharm. 2000;57(12):1141-1143.
Pyrazinamide: Allen LV Jr., Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(17):1804-1809.
Quinapril HCl: Freed AL, Silbering SB, Kolodsick KJ, Rossi DT, Mahjour M, Kingsmill CA. The development and stability assessment of extemporaneous pediatric formulations of Accupril. Int J Pharm. 2005;304(1-2):135-144.
Quinidine Sulfate: Allen LV Jr., Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(17):1804-1809.
Rifabutin: Haslam JL, Egodage KL, Chen Y, Rajewski RA, Stella V. Stability of rifabutin in two extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1999;56(4):333-336.
Rifampin: Allen LV Jr., Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(17):1804-1809.
Rifaximin: Cober MP, Johnson CE, Lee J, Currie K. Stability of extemporaneously prepared rifaximin oral suspensions. Am J Health-Syst Pharm. 2010;67(4):287-289.
Rufinamide: Hutchinson DJ, Liou Y, Best R, Zhao F. Stability of extemporaneously prepared rufinamide oral suspensions. Ann Pharmacother. 2010;44(3);462-465.
Sildenafil Citrate: Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health-Syst Pharm. 2006;63(3):254-257.
Sodium Phenylbutyrate: Caruthers RL, Johnson CE. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. Am J Health-Syst Pharm. 2007;64(14):1513-1515.
Sotalol HCl: Sidhom MB, Rivera N, Almoazen H, Taft DR, Kirshenbaum HL. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. IJPC. 2005;9(5):402-406.
Spironolactone: Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078.
Spironolactone with Hydrochlorothiazide: Allen LV Jr, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(19):2304-2309.
Sulfasalazine: Lingertat-Walsh K, Walker SE, Law S, Abesamis M, Sales P. Stability of sulfasalazine oral suspension. Can J Hosp Pharm. 2006;59(4):2304-2309.
Sumatriptan Succinate: Fish DN, Beall HD, Goodwin SD, Fox JL. Stability of sumatriptan succinate in extemporaneously prepared oral liquids. Am J Health-Syst Pharm. 1997;54(14):1619-1622.
Sunitinib Malate: Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Stability of sunitinib in oral suspension. Ann Pharmacother. 2008;42(7/8):962-966.
Tacrolimus: Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1997;54(2):178-180. Elefante A, Muindi J, West K, et al. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation. 2006;37(8):781-784.
Tadalafil: Petit RS, Johnson CE, Caruthers RL. Stability of an extemporaneously prepared tadalafil suspension. Am J Health-Syst Pharm. 2012;69:592-4.
Temozolomide: Trissel LA, Zhang Y, Koontz SE. Temozolomide stability in extemporaneously compounded oral suspensions. IJPC. 2006;10(5):396-399.
Terbinafine HCl: Abdel-Rahman SM, Nahata MC. Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C. Am J Health-Syst Pharm. 1999;56(3):243-245.
Tetracycline HCl: Allen LV Jr., Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1998;55(17):1804-1809.
Thalidomide: Kraft S, Johnson CE, Tyler RP. Stability of an extemporaneously prepared thalidomide suspension. Am J Health-Syst Pharm. 2011;69(1):56-58
Theophylline: Johnson CE, VanDekoppel S, Myers E. Stability of anhydrous theophylline in extemporaneously prepared alcohol-free oral suspensions. Am J Health-Syst Pharm. 2005;62(23):2518-2520.
Thiamine: Ensom MHH, Decarie D. Stability of thiamine in extemporaneously compounded suspensions. Can J Hosp Pharm. 2005;58(1):26-30.
Thioguanine: Aliabadi HM, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A. Stability of compounded thioguanine oral suspensions. Am J Health-Syst Pharm. 2011;68(10):900-8.
Tiagabine HCl: Nahata MC, Morosco RS. Stability of tiagabine in two oral liquid vehicles. Am J Health-Syst Pharm. 2003;60(1):75-77.
Tramadol HCl: Wagner DS, Johnson CE, Cichon-Hensley BK, DeLoach SL. Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle. Am J Health-Syst Pharm. 2003;60(12):1268-1270.
Tramadol with Acetaminophen: Johnson CE, Wagner DS, DeLoach SL, Cichon-Hensley BK. Stability of tramadol hydrochloride–acetaminophen (Ultracet) in strawberry syrup and in a sugar-free vehicle. Am J Health-Syst Pharm. 2004;61(1):54-57.
Ursodiol: Mallett MS, Hagan RL, Peters DA. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 1997;54(12):1401-1404.
Valacyclovir HCl: Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health-Syst Pharm. 1999;56(19):1957-1960.
Valganciclovir HCl: Henkin CC, Griener JC, Ten Eick AP. Stability of valganciclovir in extemporaneously compounded liquid formulations. Am J Health-Syst Pharm. 2003;60(7):687-690.
Valsartan: Physicians’ Desk Reference 64th Edition, 2010, p.2413-2418. Diovan® product information.
Vancomycin HCI: Ensom MHH, Decarie D, Lakhani A. Stability of vancomycin 25mg/mL in Ora-Sweet and water in unit-dose cups and plastic bottles at 4ºC and 25ºC. Can J Hosp Pharm. 2010;63(5):366-372.
Venlafaxine: Donnelly RF, Wong K, Goddard R, Johanson C. Stability of venlafaxine immediate-release suspension. IJPC. 2011;15(1):81-84.
Verapamil HCl: Allen LV Jr, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(19):2304-2309.
Ziprasidone Mesylate: Green K, Parish RC. Stability of ziprasidone mesylate in an extemporaneously compounded oral solution. J Pediatr Pharmcol Ther. 2010;15(2):138-141.
Zonisamide: Abobo CV, Wei B, Liang D. Stability of zonisamide in extemporaneously compounded oral suspensions. Am J Health-Syst Pharm. 2009;66:1105-9.
Previous issues of Secundum Artem (SA) are available for reference below.
CE is no longer available through Padagis.
Vol 20 No 1: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part XI
Pharmacist CPE Pharmacy Technician CE
Pharmacist CPE Pharmacy Technician CE
Vol 19 No 2: Pharmaceutical Compounding Errors
Vol 19 No 1: The ACHC-PCAB Pharmacy Accreditation Program
Vol 18 No 2: Starting A Compounding Pharmacy Practice
Vol 18 No 1: Preservatives, Antioxidants and pH
Vol 17 No 4: Certificates of Analysis, Material Safety Data Sheets and Pharmaceutical Compounding
Vol 17 No 3: Stability Of Extemporaneously Prepared Oral Liquid Formulations – Part X
Vol 17 No 2: The GAP Analysis for Nonsterile Compounding
Vol 17 No 1: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part IX
Vol 16 No 4: Compounding Foams
Vol 16 No 3: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part VIII
Vol 16 No 2: Tips & Hints for Quality Compounding – Part III
Vol 16 No 1: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part VII
Vol 15 No 4: Tips and Hints for Quality Compounding
Vol 15 No 3: Beyond-Use Dates and Stability Indicating Assay Methods in Pharmaceutical Compounding
Vol 15 No 2: Compounding with Hazardous Drugs
Vol 15 No 1: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part VI
Vol 14 No 4: Compounding Rectal Dosage Forms – Part II
Vol 14 No 3: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part V
Vol 14 No 2: Compounding Rectal Dosage Forms, Part 1
Vol 14 No 1: Stability of Extemporaneously Prepared Oral Liquid Formulations – Part IV
Vol 13 No 4: USP Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations
Vol 13 No 3: Compounding for Lacquers, Varnishes, Collodions and Protectants
Vol 13 No 2: Compounding for Gastrointestinal Disorders
Vol 13 No 1: Compounding for Otic Disorders
Vol 12 No 4: Compounding for Sports Injuries
Vol 12 No 3: Compounding for Glycerin & Propylene Glycol
Vol 12 No 2: Compounding for Scalp Disorder
Vol 12 No 1: Compounding for Wound Care
Vol 11 No 4: Compounding for Superficial Fungal Infections
Vol 11 No 3: A History of Pharmaceutical Compounding
Vol 11 No 2: Compounding for Phonophoresis
Vol 11 No 1: Compounding for Acne
Vol 10 No 4: Compounding for Iontophoresis
Vol 10 No 3: Compounding for Dermatology Patients
Vol 10 No 2: Compounding for Dentists and Dental Patients
Vol 10 No 1: Pharmaceutical Compounding Resources on the Internet
Vol 9 No 4: Compounding for Patients with Psoriasis
Vol 9 No 3: Compounding for Diabetic Patients
Vol 9 No 2: Compounding For Hospice Patients
Vol 9 No 1: Compounding For Geriatric And Arthritis Patients
Vol 8 No 4: Compounding For The Management Of Pain
Vol 8 No 3: Need For Extemporaneous Formulations In Pediatric Patients
Vol 8 No 2: Compounding For Male Andropause
Vol 8 No 1: Compounding For Hormone Replacement Therapy
Vol 7 No 4: Packaging, Storage and Distribution of Compounded Pharmaceuticals
Vol 7 No 3: Compounding, Stability and Beyond-Use Dates
Vol 7 No 2: Veterinary Compounding
Vol 7 No 1: Compounding Nasal Preparations
Vol 6 No 4: Compounding Ophthalmic Liquids
Vol 6 No 3: Inhalation Products
Vol 6 No 2: Stability of Extemporaneously Prepared Pediatric Formulations Using Ora-Plus® with Ora-Sweet® and Ora-Sweet® SF- Part III
Vol 6 No 1: Stability of Extemporaneously Prepared Pediatric Formulations Using Ora-Plus® with Ora-Sweet® and Ora-Sweet® SF – Part II
Vol 5 No 4: Stability of Extemporaneously Prepared Pediatric Formulations Using Ora-Plus® with Ora-Sweet® and Ora-Sweet® SF – Part I
Vol 5 No 3: Compounding Medication Sticks
Vol 5 No 2: Pharmaceutical Compounding Calculations
Vol 5 No 1: Pharmaceutical Compounding Tips and Hints
Vol 4 No 6: General “Good Compounding Practices” for Nonsterile Products
Vol 4 No 5: Compounding Gels
Vol 4 No 4: Compounding Capsules
Vol 4 No 3: Pharmacy Compounding Equipment
Vol 4 No 2: Troches and Lozenges
Vol 4 No 1: Emulsions
Vol 3 No 4: Compounding Suppositories: Part II
Vol 3 No 3: Compounding Suppositories: Part I
Vol 3 No 2: Compounding Topical Dosage Forms: Ointments, Creams, Pastes and Lotions
Vol 3 No 1: Compounding Oral Liquids
Vol 2 No 1: Preparation of Oral Suspensions and Syrups: Basic Concepts
Vol 1 No 2: Topical Antibiotic Dosage Forms
Vol 1 No 1: Ointment Compounding: Basic Concepts
